Pseudobulbar affect explained

Pseudobulbar affect
Synonyms:Emotional incontinence
Field:Psychiatry, neurology
Symptoms:Episodes of uncontrollable laughing, crying, or other emotional displays that may not match the patient's mental state
Duration:Few to several minutes
Causes:Traumatic brain injury, ALS, MS, dementia, etc.
Risks:Traumatic brain injury, ALS, MS, dementia, etc.
Diagnosis:During a neurological evaluation
Differential:Depression

Pseudobulbar affect (PBA), or emotional incontinence, is a type of neurological disorder characterized by uncontrollable episodes of crying or laughing. PBA occurs secondary to a neurologic disorder or brain injury. Patients may find themselves crying uncontrollably at something that is only slightly sad, being unable to stop themselves for several minutes. Episodes may also be mood-incongruent: a patient may laugh uncontrollably when angry or frustrated, for example.[1] Sometimes, the episodes may switch between emotional states, resulting in the patient crying uncontrollably before dissolving into fits of laughter.

The pseudobulbar affect, also referred to as emotional lability, should not be confused with depression that stems from emotional instability – affective dysregulation – commonly seen in mental illnesses and certain personality disorders.

Signs and symptoms

The cardinal feature of the disorder is a pathologically lowered threshold for exhibiting the behavioral response of laughter, crying, anger or all of the above. An affected individual exhibits episodes of laughter, crying, anger or a combination of these without an apparent motivating stimulus or in response to stimuli that would not have elicited such an emotional response before the onset of their underlying neurologic disorder. In some patients, the emotional response is exaggerated in intensity but is provoked by a stimulus with an emotional valence congruent with the character of the emotional display. For example, a sad stimulus provokes a pathologically exaggerated weeping response instead of a sigh, which the patient normally would have exhibited in that particular instance.[2]

However, in some other patients, the character of the emotional display can be incongruent with, and even contradictory to, the emotional valence of the provoking stimulus or may be incited by a stimulus with no clear valence. For example, a patient may laugh in response to sad news or cry in response to stimuli with no emotional undertone, or, once provoked, the episodes may switch from laughing to crying or vice versa.[3]

The symptoms of PBA can be severe, with persistent and unremitting episodes. Characteristics include:

Many people with neurologic disorders exhibit uncontrollable episodes of laughing, crying, or anger that are either exaggerated or contradictory to the context in which they occur. Where patients have significant cognitive deficits (e.g., Alzheimer's) it can be unclear whether it is true PBA as opposed to a grosser form of emotional dysregulation, but patients with intact cognition often report the symptom as disturbing. Patients report that their episodes are at best only partially amenable to voluntary control, and unless they experience a severe change of mental status, as in traumatic brain injury they often have insight into their problem and judge their emotional displays as inappropriate and out of character. The clinical effect of PBA can be severe, with unremitting and persistent symptoms that can be disabling to patients, and may significantly affect quality of life for caregivers.

Social impact

While not as profoundly disabling as the physical symptoms of the most common diseases that cause it (such as ALS), PBA may significantly influence individuals' social functioning and their relationships with others. Such sudden, frequent, extreme, uncontrollable emotional outbursts may lead to social withdrawal and interfere with activities of daily living, social and professional pursuits, and reduce overall healthcare. For example, patients with ALS and MS are often cognitively normal. However, the appearance of uncontrollable emotions is commonly associated with many additional neurological disorders such as attention deficit hyperactivity disorder, Parkinson's disease,[4] cerebral palsy,[5] autism,[6] epilepsy,[7] and migraines.[8] This may lead to avoidance of social interactions for the patient, which in turn impairs their coping mechanisms and their careers.[9] [10] [11] [12]

Depression

PBA may often be misdiagnosed as clinical depression or bipolar disorder; however, many clear distinctions exist.[13]

In depressive and bipolar disorders, crying, anger or laughter are typically indicative of mood, whereas the pathological displays of crying which occur in PBA are often in contrast to the underlying mood, or greatly in excess of the mood or eliciting stimulus. In addition, a key to differentiating depression from PBA is duration: PBA episodes are sudden, occurring in an episodic manner, while crying in depression is a more sustained presentation and closely relates to the underlying mood state. The level of control that one has over the crying, anger or other emotional displays in PBA is minimal or nonexistent, whereas for those with depression, the emotional expression (typically crying) can be modulated by the situation. Similarly, the trigger for episodes of crying in patients with PBA may be nonspecific, minimal or inappropriate to the situation, but in depression the stimulus is specific to the mood-related condition. These differences are outlined in the adjacent Table.

In some cases, depressed mood and PBA may co-exist. Since depression is one of the most common emotional changes in patients with neurodegenerative disease or post-stroke sequelae, it is often comorbid with PBA. Comorbidity implies that depression is distinct from PBA and is not necessary for, nor does it exclude, a diagnosis of PBA.[14]

Causes

The specific pathophysiology involved in this frequently debilitating condition is still under investigation; the primary pathogenic mechanisms of PBA remain controversial.[15] One hypothesis, established by early researchers such as Wilson and Oppenheim, placed emphasis on the role of the corticobulbar pathways in modulating emotional expression in a top-down model, and theorized that PBA occurs when bilateral lesions in the descending corticobulbar tract cause failure of voluntary control of emotion, which leads to the disinhibition, or release, of laughing/crying centers in the brainstem.[16] Other theories implicate the prefrontal cortex.[17]

Secondary condition

PBA is a condition that occurs secondary to neurological disease or brain injury, and is thought to result from disruptions of neural networks that control the generation and regulation of motor output of emotions. PBA is most commonly observed in people with neurologic injuries such as traumatic brain injury (TBI) and stroke,[16] [18] and neurologic diseases such as dementias including Alzheimer's disease, attention deficit hyperactivity disorder (ADHD),[19] [20] multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). It has been reported as a symptom of hyperthyroidism, Graves' disease, or hypothyroidism in combination with depression.[21]

PBA has also been observed in association with a variety of other brain disorders, including brain tumors, Wilson's disease, syphilitic pseudobulbar palsy, and various encephalitides. Rarer conditions associated with PBA include gelastic epilepsy, dacrystic epilepsy, central pontine myelinolysis, olivopontinocerebellar atrophy, lipid storage diseases, chemical exposure (e.g., nitrous oxide and insecticides), fou rire prodromique, and Angelman syndrome.

It is hypothesized that these primary neurologic injuries and diseases affect chemical signaling in the brain, which in turn disrupts the neurologic pathways that control emotional expression.[22] [23] [24]

Stroke

PBA is one of the most frequently reported post-stroke behavioral disorders, with a range of reported prevalence rates from 28% to 52%.[25] [26] [27] The higher prevalence rates tend to be reported in stroke patients who are older or who have a history of prior stroke.[28] [29] The relationship between post-stroke depression and PBA is complicated, because the depressive syndrome also occurs with high frequency in stroke survivors. Post-stroke patients with PBA are more depressed than post-stroke patients without PBA, and the presence of a depressive syndrome may exacerbate the weeping side of PBA symptoms.[30]

Multiple sclerosis

Recent studies suggest that approximately 10% of patients with multiple sclerosis (MS) will experience at least one episode of emotional lability.[31] [32] PBA is generally associated with later stages of the disease (chronic progressive phase).[27] PBA in MS patients is associated with more severe intellectual deterioration, physical disability, and neurological disability.[33]

Amyotrophic lateral sclerosis

A study designed specifically to survey for prevalence found that 49% of patients with amyotrophic lateral sclerosis (ALS) also had PBA. PBA does not appear to be associated with duration of ALS.[34] [35] It is a symptom of ALS that many patients are unaware of and do not receive information about from their physician.[36]

Traumatic brain injury

One study of 301 consecutive cases in a clinic setting reported a 5% prevalence. PBA occurred in patients with more severe head injury, and coincided with other neurological features suggestive of pseudobulbar palsy.[37]

The Brain Injury Association of America (BIAA) indicates that approximately 80% of survey respondents experience symptoms of PBA.[38] Results from a recent investigation estimate the prevalence of PBA associated with traumatic brain injury to exceed more than 55% of survivors.[39]

Treatment

Education of patients, families, and caregivers is an important component of the appropriate treatment of PBA. Crying associated with PBA may be incorrectly interpreted as depression; laughter may be embarrassing, anger can be debilitating. It is therefore critical for families and caregivers to recognize the pathological nature of PBA and the reassurance that this is an involuntary syndrome that is manageable. Traditionally, antidepressants such as sertraline,[40] fluoxetine,[41] citalopram,[42] nortriptyline[43] and amitriptyline[44] have been prescribed with some efficacy.

Medication

Dextromethorphan hydrobromide affects the signals in the brain that trigger the cough reflex. It is used as a cough suppressant, although it can sometimes be used, medicinally, as a pain reliever, and is also used as a recreational drug.[45]

Quinidine sulfate affects the way the heart beats, and is generally used in people with certain heart rhythm disorders. It is also used to treat malaria.[46] Quinidine sulfate, as a metabolic inhibitor, "increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan," enabling therapeutic dextromethorphan concentrations.[47]

Dextromethorphan/quinidine is a combination of these two generic drugs, and is the first FDA-approved drug for the treatment of PBA, approved on October 29, 2010.[48]

In the pivotal multicenter study that led to its approval, the "Objectives...[were] to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 [Dextromethorphan/quinidine combination]...when compared to placebo."[49] The conditions and results of that study are as follows:

Epidemiology

Prevalence estimates place the number of people with PBA between 1.5 and 2 million in the United States alone, which would be less than 1% of the U.S. population even at the high end of the estimate. Some argue that the number is probably higher and that clinicians underdiagnose PBA.[50] However, the prevalence estimate of 2 million is based on an online survey. Self-selected computer-savvy patients in at-risk groups evaluated their own symptoms and submitted their self-diagnoses. No doctor or clinic confirmed the data. Motivation to participate could have been influenced by the presence of symptoms, which would have skewed the results. The actual prevalence could very well be quite a bit lower than estimated.[51]

History

The Expression of the Emotions in Man and Animals by Charles Darwin was published in 1872.[52] In Chapter VI, "Special Expressions of Man: Suffering and Weeping", Darwin discusses cultural variations in the acceptability of weeping and the wide differences in individual responses to suffering. The chapter contains the following sentence:

Terminology

Historically, there have been a variety of terms used for the disorder, including pseudobulbar affect, pathological laughter and crying, emotional lability, emotionalism, emotional dysregulation, or more recently, involuntary emotional expression disorder.[53] The term pseudobulbar (pseudo- + bulbar) came from the idea that the symptoms seemed similar to those caused by a bulbar lesion (that is, a lesion in the medulla oblongata).

Terms such as forced crying, involuntary crying, pathological emotionality, and emotional incontinence have also been used, although less frequently.[54]

In popular culture

Arthur Fleck, the central character of the 2019 film Joker, displays signs of pseudobulbar affect,[55] [56] which are said to be what Joaquin Phoenix used as inspiration for his character's signature laugh.

In the 2019 movie Parasite, the character Ki-woo sustains head trauma, and although it is not clearly mentioned that he's affected by pseudobulbar affect, he mentions not being able to stop laughing when thinking about all the events that occur in the movie.

In the 2020 movie Naan Sirithal, the character Gandhi (Hiphop Tamizha Adhi) suffers from pseudobulbar affect due to all the stress he suffers from various parts of his life gets accumulated and starts to laugh uncontrollably.

In the medical television show House, season 7, episode 8 ("Small Sacrifices"), the character Ramon Silva, played by Kuno Becker displays pseudobulbar affect, with uncontrollable incongruent laughter, while having the Marburg variety of multiple sclerosis.

In season 3, episode 9 of The Good Fight, the character Brenda DeCarlo, an external auditor, displays pseudobulbar affect, with uncontrollable incongruent laughter.

See also

External links

Notes and References

  1. Ramirez-Bermudez . Jesús . Perez-Esparza . Rodrigo . Flores . Jose . Leon-Ortiz . Pablo . Corona . Teresa . Restrepo-Martínez . Miguel . 2022-04-01 . Involuntary Emotional Expression Disorder in a Patient With Toluene Leukoencephalopathy . Revista Colombiana de Psiquiatría . 51 . 2 . 163–166 . 10.1016/j.rcp.2020.10.001 . 33735011 . 230547846 . 0034-7450.
  2. Ahmed . Aiesha . Simmons . Zachary . 2013 . Pseudobulbar affect: prevalence and management . Therapeutics and Clinical Risk Management . 9 . 483–489 . 10.2147/TCRM.S53906 . free . 1176-6336 . 3849173 . 24348042.
  3. Parvizi J . Diagnosis and management of pathological laughter and crying . . 81 . 11 . 1482–1486 . 2006 . 17120404 . 10.4065/81.11.1482 . vanc. Archiniegas DB . Bernardini GL . Hoffman MW . 4 . Mohr . JP . Rapoport . MJ . Schmahmann . JD . Silver . JM . Tuhrim . S . free .
  4. Latoo. Javed. Mistry. Minal. Dunne. Francis J. 2013. Often overlooked neuropsychiatric syndromes in Parkinson's disease. British Journal of Medical Practitioners. 6. 1. 4 November 2014. live. https://web.archive.org/web/20141104065556/http://www.bjmp.org/content/often-overlooked-neuropsychiatric-syndromes-parkinson-s-disease. 4 November 2014.
  5. Book: Treatment of Cerebral Palsy and Motor Delay. Levitt S . 2013. Wiley. 9781118699782. 4 November 2014. live. https://web.archive.org/web/20170220010953/https://books.google.com/books?id=8sgSHF3E0aMC. 20 February 2017.
  6. Book: Conditions in Occupational Therapy: Effect on Occupational Performance. Atchison, B.. Dirette, D.K.. 2007. Lippincott Williams & Wilkins. 9780781754873. 40. 4 November 2014. live. https://web.archive.org/web/20170220011142/https://books.google.com/books?id=tAgNQ2rAj_8C. 20 February 2017.
  7. Devinsky. O. Vazquez. B. 1993. Behavioral changes associated with epilepsy . Neurologic Clinics. 11. 1. 127–49 . 8441366. 10.1016/S0733-8619(18)30173-7. free.
  8. Web site: Medscape: Medscape Access. medscape.com. 4 November 2014. live. https://web.archive.org/web/20151102233910/http://www.medscape.com/viewarticle/767947_3. 2 November 2015.
  9. Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA . A self report measure of affective lability . . 63 . 1 . 89–93 . 1997 . 9221973 . 10.1136/jnnp.63.1.89 . 2169647 .
  10. Shaibani AT, Sabbagh MN, Doody R . Rachelle Doody. Laughter and crying in neurologic disorders . Neuropsychiatry, Neuropsychology & Behavioral Neurology . 7 . 243–250 . 1994 .
  11. Black DW . Pathological laughter. A review of the literature . . 170 . 2 . 67–71 . 1982 . 7057172 . 10.1097/00005053-198202000-00001. 25616832 .
  12. Green RL . Regulation of affect . Seminars in Clinical Neuropsychiatry . 3 . 3 . 195–200 . 1998 . 10085207.
  13. Kekere . Victor . Qureshi . Danish . Thanju . Amod . Fouron . Patrice . Olupona . Tolulope . Pseudobulbar Affect Mimicking Depression: A Case Report . Cureus . 2022 . 14 . 6 . e26235 . 10.7759/cureus.26235 . free . 2168-8184 . 9312808 . 35911367.
  14. Espiridion . Eduardo D . Risos . Kyle N . A Major Depressive Disorder in a Patient with Pseudobulbar Affect . Cureus . 2018 . 10 . 12 . e3746 . 10.7759/cureus.3746 . free . 2168-8184 . 6388818 . 30820367.
  15. Archiniegas DB, Topkoff J . The neuropsychiatry of pathologic affect: an approach to evaluation and treatment . Seminars in Clinical Neuropsychiatry . 5 . 4 . 290–306 . 2000 . 10.1053/scnp.2000.9554 . 11291026.
  16. Parvizi J, Anderson SW, Martin CO, Damasio H, Damasio AR . Pathological laughter and crying: a link to the cerebellum . . 124 . Pt 9 . 1708–1719 . 2001 . 11522574 . 10.1093/brain/124.9.1708 . free .
  17. McCullagh S, Moore M, Gawel M, Feinstein A . 1999 . Pathological laughing and crying in amyotrophic lateral sclerosis: an association with prefrontal cognitive dysfunction . . 169 . 1–2. 43–48 . 10.1016/s0022-510x(99)00214-2. 10540006 . 34234732 .
  18. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study . . 150 . 2 . 286–293 . 1993 . 8422080 . 10.1176/ajp.150.2.286.
  19. 10.1016/j.jad.2012.10.011 . Emotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder . 2013 . Skirrow . Caroline . Asherson . Philip . . 147 . 80–6 . 23218897 . 1–3.
  20. Oscar L. . Lopez . Maria P. . Gonzalez . James T. . Becker . Charles F. . Reynolds . Abraham . Sudilovsky . Steven T. . DeKosky . Symptoms of depression and psychosis in Alzheimer's disease and frontotemporal dementia: exploration of underlying mechanisms . Neuropsychiatry, Neuropsychology & Behavioral Neurology . 9 . 3 . 154–161 . 1996.
  21. Tremont Geogffery . Neurbehavioral Functioning in Thyroid Disorders. Medicine and Health. Web site: The Warren Alpert Medical School of Brown University . 2015-06-17 . live . https://web.archive.org/web/20151223155701/http://med.brown.edu/neurology/articles/gt31803.pdf . 2015-12-23 .
  22. Greenamyre JT . The role of glutamate in neurotransmission and in neurologic disease . Archives of Neurology . 43 . 10 . 1058–1063 . 1986 . 2428340 . 10.1001/archneur.1986.00520100062016.
  23. Bittigau P, Ikonomidou C . Glutamate in neurologic diseases . . 12 . 8 . 461–485 . 1997 . 9430311 . 10.1177/088307389701200802 . 1258390 .
  24. Mattson MP . Excitotoxic and excitoprotective mechanism: abundant targets for the prevention and treatment of neurodegenerative disorders . . 3 . 2 . 65–94 . 2003 . 12728191 . 10.1385/NMM:3:2:65. 13181891 .
  25. House A, Dennis M, Molyneux A, Warlow C, Hawton K . Emotionalism after stroke . . 298 . 6679 . 991–994 . 1989 . 2499390 . 10.1136/bmj.298.6679.991 . 1836312 .
  26. Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K . Fluoxetine improves emotional incontinence . . 6 . 3 . 267–270 . 1992 . 1581749 . 10.3109/02699059209029668 .
  27. Feinstein A, Feinstein K, Gray T, O'Connor P . Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis . Archives of Neurology . 54 . 9 . 1116–1121 . 1997 . 9311355 . 10.1001/archneur.1997.00550210050012 .
  28. Kim JS . Post-stroke emotional incontinence after small lenticulocapsular stroke: correlation with lesion location . . 249 . 7 . 805–810 . 2002 . 12140660 . 10.1007/s00415-002-0714-4. 22019561 .
  29. Harris Y . Psychiatric symptoms in dementia associated with stroke: a case-control analysis among predominantly African-American patients . Journal of the National Medical Association . 86 . 9 . 697–702 . 1994 . 7966434 . 2607578 . vanc. Gorelick PB . Cohen D . Dollear W . 4 . Forman . H . Freels . S.
  30. Ross ED, Stewart RS . Pathological display of affect in patients with depression and right frontal brain damage. An alternative mechanism . Journal of Nervous and Mental Disease . 175 . 3 . 165–172 . 1987 . 3819712 . 10.1097/00005053-198703000-00007 . 22177650 .
  31. Haupt . Emotional lability, intrusiveness, and catastrophic reactions . International Psychogeriatrics . 8 . Suppl 3 . 409–414 . 1996 . 9154598 . 10.1017/S1041610297003736. 23055485 .
  32. Sloan RL, Brown KW, Pentland B . Fluoxetine as a treatment for emotional lability after brain injury . Brain Injury . 6 . 4 . 315–319 . 1992 . 1638265 . 10.3109/02699059209034945 .
  33. Surridge D . An investigation into some psychiatric aspects of multiple sclerosis . . 115 . 524 . 749–764 . 1969 . 5806869 . 10.1192/bjp.115.524.749. 10900202 .
  34. Caroscio JT, Mulvihill MN, Sterling R, Abrams B . Amyotrophic lateral sclerosis . Neurologic Clinics . 5 . 1 . 1–8 . 1987 . 3561382 . 10.1016/S0733-8619(18)30931-9 .
  35. Gallagher JP . Pathologic laughter and crying in ALS: a search for their origin . . 80 . 2 . 114–117 . 1989 . 2816272 . 10.1111/j.1600-0404.1989.tb03851.x . 32590792 .
  36. Wicks P, Frost J. ALS patients request more information about cognitive symptoms . . 15 . 5 . 497–500 . 2008 . 18325023 . 10.1111/j.1468-1331.2008.02107.x . 205580014 . free .
  37. Zeilig G, Drubach DA, Katz-Zeilig M, Karatinos J . Pathological laughter and crying in patients with closed traumatic brain injury . Brain Injury . 10 . 8 . 591–597 . 1996 . 8836516 . 10.1080/026990596124160 .
  38. Web site: BIAA Survey: Pseudobulbar Affect in Brain Injury. Summary report. . December 2010 . 2011-08-16 . dead . https://web.archive.org/web/20110927122020/http://www.biausa.org/_literature_77385/1-7-2011_PBA_Survey_Results . 2011-09-27 .
  39. Fellus JL, Kantor D, Kaye RE . PRISM registry: A novel research tool to determine the prevalence of pseudobulbar affect . European Journal of Neurology . 19 . S1 . 85–90 . 2012 . 10.1111/j.1468-1331.2012.03887.x . free .
  40. 10.1002/(SICI)1099-1166(199908)14:8<681::AID-GPS49>3.0.CO;2-Z . Sertraline in stroke-associated lability of mood . 1999 . Burns . Alistair . Russell . Eve . Stratton-Powell . Hilary . Tyrell . Pippa . O'Neill . Paul . Baldwin . Robert . International Journal of Geriatric Psychiatry . 14 . 8 . 681–5 . 10489659. 40410983 .
  41. 10.1111/j.1600-0447.1998.tb10119.x . Fluoxetine as a treatment for post-stroke emotionalism . 1998 . Brown . K. W. . Sloan . R. L. . Pentland . B. . . 98 . 6 . 455–8 . 9879787. 24075238 .
  42. 10.1016/0140-6736(93)92696-Q . Citalopram for post-stroke pathological crying . 1993 . Andersen . G . Vestergaard . K . Riis . J. O. . . 342 . 8875 . 837–9 . 8104273. 24445214 .
  43. 8422080 . 1993 . Robinson . RG . Parikh . RM . Lipsey . JR . Starkstein . SE . Price . TR . Pathological laughing and crying following stroke: Validation of a measurement scale and a double-blind treatment study . 150 . 2 . 286–93 . American Journal of Psychiatry . 10.1176/ajp.150.2.286.
  44. 10.1056/NEJM198506063122303 . Treatment of Pathologic Laughing and Weeping with Amitriptyline . 1985 . Schiffer . Randolph B. . Herndon . Robert M. . Rudick . Richard A. . . 312 . 23 . 1480–2 . 3887172.
  45. Web site: Dextromethorphan (DXM) . Cesar.umd.edu . 2016-02-18 . live . https://web.archive.org/web/20130726211404/http://www.cesar.umd.edu/cesar/drugs/dxm.asp . 2013-07-26 .
  46. Web site: Quinidine sulfate . . PDRhealth™ . 2016 . 2016-02-18 . live . https://web.archive.org/web/20150905152342/http://www.pdrhealth.com/drugs/quinidine-sulfate . 2015-09-05 .
  47. Web site: Label: NUEDEXTA- dextromethorphan hydrobromide and quinidine sulfate capsule, gelatin coated . . U.S. National Library of Medicine, DailyMed . 2015-01-30 . 2016-02-18 . live . https://web.archive.org/web/20160303160859/http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=484e0918-3442-49dc-8ccf-177f1f3ee9f3 . 2016-03-03 .
  48. Web site: Nuedexta, FDA Approval History . Drugs.com . January 2015 . 2016-02-18 . live . https://web.archive.org/web/20160303235103/http://www.drugs.com/pro/nuedexta.html . 2016-03-03 .
  49. Web site: Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS (STAR) . . . June 2013 . 2016-02-19 . live . https://web.archive.org/web/20160302154633/https://clinicaltrials.gov/ct2/show/study/NCT00573443?show_locs=Y&sect=X4326#locn . 2016-03-02 .
  50. Archiniegas DB, Lauterbach EC, Anderson KE, Chow TW, Flashman LA, Hurley RA, Kaufer DI, McAllister TW, Reeve A, Schiffer RB, Silver JM . 4 . The differential diagnosis of pseudobulbar affect (PBA). Distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting . CNS Spectrums . 10 . 5 . 1–16 . 2005 . 15962457 . 10.1017/S1092852900026602 . 45811704 .
  51. Brooks . Benjamin Rix. Crumpacker. David. Fellus . Jonathan . Kantor . Daniel. Kaye . Randall E. Aug 21, 2013. PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions . PLOS ONE. . 8. 8. e72232. 10.1371/journal.pone.0072232. 3749118 . 23991068. 2013PLoSO...872232B. free.
  52. Web site: Expression of the Emotions . Darwin . Charles . 1872 . 2008 . 2013-10-26 . live . https://web.archive.org/web/20131118070054/http://darwin-online.org.uk/content/frameset?itemID=F1142&viewtype=text&pageseq=1 . 2013-11-18 .
  53. Cummings J, Arciniegas D, Brooks B, Herndon R, Lauterbach E, Pioro E, Robinson R, Scharre D, Schiffer R, Weintraub D . Defining and diagnosing involuntary emotional expression disorder . CNS Spectrums . 11 . 6 . 1–7 . 2006 . 16816786 . 10.1017/S1092852900026614 . 10565577 .
  54. Dark FL, McGrath JJ, Ron MA . Pathological laughing and crying . . 30 . 4 . 472–479 . 1996 . 8887697 . 10.3109/00048679609065020 . 30407097 .
  55. Web site: Joaquin Phoenix Reveals the Dark, Real World Origin of His Joker's Laugh . CBR . 14 August 2019 . 12 October 2019.
  56. Skryabin . Valentin Yurievich . Analysing Joker: an attempt to establish diagnosis for a film icon . BJPsych Bulletin . 2021 . 45 . 6 . 329–332 . 10.1192/bjb.2020.146 . 2056-4694 . 8727382 . 33407973.